prasugrel Side Effects
Also known as: Effient
Analysis of 2,254 adverse event reports submitted to the FDA from 2009 to 2025.
Total Reports
2,254
Death-Related
251
11.1% of reports
Hospitalizations
1,074
47.6% of reports
Top Indication
Product Used For Unknown Indication
Most Reported Adverse Reactions
Who Reports Side Effects
Gender Distribution
Age Distribution
Reporting Trend by Year
Reactions in Death Reports
Top reactions reported in 251 reports where death was an outcome. These are voluntarily reported and do not establish causation.
| Reaction | Reports |
|---|---|
| DEATH | 40 |
| COMPLETED SUICIDE | 24 |
| CEREBRAL HAEMORRHAGE | 22 |
| SEPSIS | 21 |
| RENAL FAILURE | 16 |
| CARDIAC ARREST | 15 |
| OFF LABEL USE | 14 |
| ACUTE MYOCARDIAL INFARCTION | 13 |
| INTRAVENTRICULAR HAEMORRHAGE | 12 |
| RESPIRATORY FAILURE | 12 |
| DYSPNOEA | 11 |
| SYSTEMIC INFLAMMATORY RESPONSE SYNDROME | 11 |
| TOXICITY TO VARIOUS AGENTS | 11 |
| DISEASE PROGRESSION | 10 |
| RHABDOMYOLYSIS | 10 |
| VASCULAR STENT THROMBOSIS | 10 |
| BLOOD GLUCOSE INCREASED | 9 |
| DRUG INTERACTION | 9 |
| GASTROINTESTINAL HAEMORRHAGE | 9 |
| HAEMORRHAGE | 9 |
Reactions in Hospitalization Reports
Top reactions in 1,074 reports where hospitalization was an outcome.
| Reaction | Reports |
|---|---|
| MYOCARDIAL INFARCTION | 109 |
| ACUTE MYOCARDIAL INFARCTION | 80 |
| DYSPNOEA | 63 |
| CHEST PAIN | 61 |
| GASTROINTESTINAL HAEMORRHAGE | 56 |
| NAUSEA | 54 |
| DRUG INEFFECTIVE | 44 |
| HYPERTENSION | 44 |
| OFF LABEL USE | 43 |
| DIZZINESS | 38 |
| VOMITING | 36 |
| CORONARY ARTERY DISEASE | 34 |
| HEADACHE | 33 |
| VASCULAR STENT THROMBOSIS | 33 |
| ASTHENIA | 32 |
| ANAEMIA | 31 |
| PNEUMONIA | 31 |
| RHABDOMYOLYSIS | 30 |
| DIARRHOEA | 29 |
| ACUTE KIDNEY INJURY | 27 |
Nearby — Related Medications
What the FAERS Data Reveals About prasugrel Side Effects
The FDA Adverse Event Reporting System (FAERS) contains 2,254 voluntary reports linked to prasugrel and its brand equivalents (Effient), spanning 2009 through 2025. Of those, 251 (11.1%) listed death as an outcome and 1,074 (47.6%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.
Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 33% were female and 66% male; age distribution skews toward 45-64, with 712 reports in that bracket. The single most reported reaction is myocardial infarction with 172 submissions, followed by drug ineffective and dyspnoea.
FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice — speak with a licensed clinician about any side-effect concerns.
Read our methodology — how this data is sourced, computed, and verified.